Q BioMed Inc (QBIO)

[MetaMonster]

What about 10k

[MetaMonster]

Would surely bring value if CEO would buyback open market shares

[The Night Stalker]

they are so broke to pay to release filings. they were bluffing about the partner

[The Night Stalker]

they are so broke to pay to release filings. they were bluffing about the partner

[Broadway1430]

Sorry wrong board

[Broadway1430]

Leandro,
Thank you for your shareholder letter. I make this post to
once again ask you, respectfully, to consider an open market purchase
of Iqst shares. I know you hold a very large number of non open
market purchased shares but the powerful signal you would
send , the ceo buying his stock in the open market, would be
so meaningful. Please at least consider this move which all of
would appreciate so much. Thank you.

[Money hunt]

Nothing.. Managaement burned all investors

[Money hunt]

Qbio Managaement is completely useless, if this news was real we would be at .10 eyes closed and have a value of 15m market cap

[Money hunt]

This piece of garbage is going to collapse, no one interested in this trash

[MetaMonster]

Is that pre market pressure coming

[Broadway1430]

Thank you for the article. Please continue to keep us informed.

[ThinkBig18]

Qbio is ready$$$$$

[ThinkBig18]

News has been simmering all weekend watch what is in store tomorrow

[ThinkBig18]

https://www.proactiveinvestors.com/companies/news/1012173/q-biomed-receives-us-patent-and-notice-of-allowance-in-europe-for-uttroside-b-seeks-ways-to-boost-shareholder-value-1012173.html?rel=scroll

[ThinkBig18]

Whales bottom feeding before FDA explosion

[ThinkBig18]

Unless biotech sharks smell blood in the middle of the ocean

[ThinkBig18]

From rags to the richest that's what biotechs are all about

[ThinkBig18]

Don't worry 100's of millions coming with FDA approval

[The Night Stalker]

they need money badly

[Money hunt]

It’s green $$$$$$$$$

[IMNOTSURE]

Hardly a collapse. Green and decent volume finally. I would call it accumulation.

[Money hunt]

What the hell news is out and it collapses

[Helter Skelter]

And these folks will face criminal charges as well?

Q BioMed announced in 2021 that it has received Orphan Drug Status from the FDA. Q BioMed Inc. is prosecuting patents in multiple jurisdictions and has received patents from Canada, Korea and Japan and has now received notice of an allowable patent in the USA. The Patent is titled "Uttroside-B and Derivatives Thereof as Therapeutics for Hepatocellular Carcinoma (HCC)". Q BioMed has the exclusive rights to the technology through an agreement with the Rajiv Gandhi Centre for Biotechnology, an Autonomous Institute under the Department of Biotechnology, Government of India, and the Oklahoma Medical Research Foundation.

Nonsense.

[GeorgeTheStub]

well, today's pr is just a rehash of the previous announcement concerning the patent...apparently the "cure for cancer" patent is worthless, no matter how management tries to spin it. Would not at all be surprised to read soon that the "research and data results" were manipulated and falsified, and that management is facing criminal charges.

[Broadway1430]

Let’s be happy for now. At least it’s still breathing, and with a European
patent to go with the others. Hope something is brewing at Mannin.

[The Night Stalker]

cash strapped biotech

[droopyeyes]

Huge News today !!

Let's close at .02!!!


imo

[Helter Skelter]

Sell an Asset, Sell Product, Funding, Partner and/or Buyout. They do have options. $QBIO

[Helter Skelter]

"The current microcap and biotech funding climate is making raising capital very challenging and keeping up with the considerable expense of public company operations and professional fees has resulted in them not being able to timely file or annual report. The company is working on remedying that as soon as possible"

Not a good way to finish a PR...tailing off, spelled "our" wrong, left a period off the final sentence, lol...sell an asset. SELL SOMETHING. Number one priority is to get a SALESFORCE that can sell the one product that they have FDA approval on...JMO

Need funding for the salesforce, though. So MONEY is the still the number one priority.

[karimo]

Denis don't have money to fill 10k???!!!

[Helter Skelter]

Possible...the period(s), not filed Q4 in the Annual Report, is already over 3 months old...can't believe they don't have the funds to get that 10-K done...CEO sitting on his beach in the Caymans...maybe needs to move to cheaper digs? ;)

Sell an asset.

[x-ray-eyes]

I had a thought on the 10-K, what if they are delaying the filing as they're in discussions with partners and one option would be for a large firm to take over the whole company? That would be sweet, $$$, imo

[x-ray-eyes]

Agree, best part of the PR is Dennis is currently in talks to monetize the Patents, meaning we should see something on that front sooner rather than later, imo

[Helter Skelter]

At least acquire (Q sells) an asset for multi-millions...I don't know which one to sell, though, they (products) all have great potential...need funds or partners quick-like!

Get that 10-K filed.

$QBIO

[x-ray-eyes]

Good, I'd rather add on lower prices. Dennis said in the PR they are evaluating partnerships. I think a larger company will partner or acquire. Either way, the current PPS is grossly undervalued.

imo -- glta

[x-ray-eyes]

With the Patents and Mannin equity stake, a larger company will partner or acquire sooner rather than later. imo

[karimo]

Nice news and red ????

[x-ray-eyes]

Patent received from the U.S. and Notice of Allowance in Europe, increases the possibilities for a larger company to partner or acquire, imo

https://www.prnewswire.com/news-releases/q-biomed-inc-chemotherapeutic-uttroside-b-receives-patent-from-united-states-patent-office-and-notice-of-allowance-for-europe-301797482.html

[Helter Skelter]

NEWS! >> Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Patent from United States Patent Office and Notice of Allowance for Europe

Company's Liver Cancer Drug Candidate IP Portfolio strengthened

Company provides operational update on strategic opportunities

NEW YORK , April 14, 2023 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO) a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare sector, asset Uttroside B has received a patent in the United States and a notice of allowance in Europe , adding to the already issued patents in Korea , Canada and Japan . In addition, recent results from pre-clinical pharmacokinetic testing have been very encouraging and the data supports advancing the program. Uttroside B shows tremendous value in the Liver Cancer Market and has received Orphan Drug designation from the FDA.

The America Cancer Society (www.cancer.org) reported in this year alone, an estimated 42,000 adults in the United States will be diagnosed with primary liver cancer. It is also estimated that 30,000 deaths from this disease will occur this year. The 5-year survival rate is 20%, compared to just 3% 40 years ago. For the 44% of people who are diagnosed with liver cancer at an early stage, the 5-year survival rate is 34%. There is significant demand for better therapeutic alternatives in the space. Q BioMed has the exclusive rights to the technology through an agreement with the Rajiv Gandhi Centre for Biotechnology , an Autonomous Institute under the Department of Biotechnology , Government ofIndia,and the Oklahoma Medical Research Foundation .

In addition to successfully prosecuting its IP portfolio the company is engaged in finding strategic opportunities to best preserve and create value for its shareholders.

Denis Corin , QBioMed Inc. CEO said, "We believe in the inherent value we have created in our pipeline. With the assistance of bankers and funding partners we are evaluating strategic opportunities including financing, mergers, and asset joint ventures or sale of assets in order to maximize value for our shareholders in a very difficult market."

The company has an approved non-opioid cancer pain palliation asset that is an effective therapeutic, it's a non-opiate and can save hospitals millions of dollars in economic outcome improvements. In addition, it has a very promising liver cancer chemotherapeutic that has been granted US orphan drug status and several international patents, and recently was also granted a patent in USA. The plan is to advance this asset into the clinic in a non-US country where the government is offering 43% cash rebate and combined with US dollar strength would allow us to complete that clinical phase for 50% of the typical cost and potentially in a shorter timeframe. It previously reported the remarkable potency of Uttroside-B against liver cancer cells and believes it could be a very valuable drug candidate in the liver cancer market which has few therapeutics for a growing patient population.

QBioMed has an equity stake in Mannin Research valued at approximately $3.5M USD . This asset value is expected to rise significantly as they advance their programs assisted by non-dilutive government funding already amounting to over $15M and which could exceed $100M over the next year. Data from the Mannin planned ARDS trial will support the filings for further indications, including kidney disease and glaucoma. Combined, the addressable market for these therapies is over $150 billion a year.

The company believes these assets are far more valuable than the current market cap of the company and are determined to find a way to recognize that value for its shareholders and those that made these assets into promising therapeutics that could help many people around the world.

While the company believes these corporate activities are building value, it is of course aware of the dismal stock performance. Unfortunately, its cap and debt structure coupled with the general macro-market uncertainty and specifically the biotech market capitulation, has resulted in a valuation for QBIO that they maintain, is not reflective of the inherent asset value within their portfolio. The current microcap and biotech funding climate is making raising capital very challenging and keeping up with the considerable expense of public company operations and professional fees has resulted in them not being able to timely file or annual report. The company is working on remedying that as soon as possible

About Q BioMed Inc.

Q BioMed Inc is a biotech acceleration and commercial stage company. Q BioMed is focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q BioMed is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital needed to ensure they meet their developmental potential, enabling them to provide products to patients in need.

[JJZander]

Nice news

[i_like_bb_stock]

nice news former run to 06 in February https://www.otcmarkets.com/stock/QBIO/news/Q-BioMed-Inc-Chemotherapeutic-Uttroside-B-Receives-Patent-from-United-States-Patent-Office-and-Notice-of-Allowance-for-E?id=396625

[karimo]

Something in the air $$$$$$

[Money hunt]

So?? Where’s the news dude!!!!

[The Night Stalker]

runs big on pump news

[The Night Stalker]

its a cash trapped otc biotech

[karimo]

QBIO has to file the 10-k after the NT-10K? 15 days for actual 10-K to be filed maybe right????

[Canna-Biz-Invest]

Time for this to start cooking again....$QBIO

[The Night Stalker]

break the silence

[The Night Stalker]

u new to this

[Broadway1430]

If you read the PR where we are now 15% owners of Mannin,
would you agree that a Mannin IPO is a distinct possibility
in the not too distant future.